Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2016

ESMO 2016, the world's premier congress in medical oncology will be taking place in Copenhagen from the 7 - 11 October 2016.

The congress will attract an international community of experts, across disciplines and all focused on finding the most effective cancer treatment solutions available today.

This is the ultimate goal of ESMO 2016 and we count on our Industry Partners active in oncology to help us again further our science and improve the lives of patients through continued education.

Fast Facts: ESMO 2014 Congress

  • 19 809 participants, 134 countries
  • 5480 m² exhibition space, 118 exhibitors
  • 460 Invited speakers
  • 21 tracks, 180 sessions
  • 2754 submitted abstracts

How can I participate in 2016?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate your presence at our conference.

Contact the ESMO Events Sponsorship Team for more details and we look forward to hearing from you!

Who has already signed up?

We gratefully acknowledge the valuable contribution of the following organisations in the ESMO 2016 Congress through their presence in the exhibition hall, organisation of sponsored sessions, or via sponsorship activities (as of August 2016):


  • AbbVie Inc.
  • Advanced Accelerator Applications
  • Agena Bioscience GmbH
  • Agendia N.V.
  • Amgen (Europe) GmbH
  • Ariad Pharmaceuticals Inc.
  • Astellas Pharma Europe Ltd.
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Biocartis NV
  • BMJ Publishing Group Ltd.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cancer Intelligence
  • Celgene
  • Celldex Therapeutics, Inc.
  • Chiltern International Ltd.
  • Clinical Research Malaysia(CRM)
  • Clovis Oncology
  • Daiichi-Sankyo Europe GmbH
  • Elsevier Ltd.
  • European Medical Journal
  • Exelixis
  • F.Hoffmann - La Roche Ltd.
  • Fresenius Kabi Deutschland GmbH
  • GATC Biotech AG
  • Genomic Health International Sarl
  • HalioDx
  • Helsinn Healthcare SA
  • Helsinn Integrative Care
  • Hospira Ltd.
  • Imedex, Inc.
  • IMS Health GmbH & Co OHG
  • Incyte Corporation
  • Ipsen Innovation
  • The JAMA Network
  • Janssen Pharmaceutica NV
  • S.Karger AG
  • Lilly Oncology
  • Medac GmbH
  • Median Technologies
  • Medical Prognosis Institute (MPI)
  • Medivation, Inc.
  • Merck Serono
  • Merck/Pfizer Alliance
  • Molecular Health GmbH
  • MSD
  • Myriad Genetics GmbH
  • NanoString Technologies Europe Limited
  • Novartis Oncology
  • Novella Clinical, a Quintiles company
  • Nutricia
  • OBI Pharma Inc.
  • OncoDNA
  • Oncology Venture
  • Oncotherm GmbH
  • OSE Immunotherapeutics
  • Oxford University Press
  • Paxman Coolers Ltd.
  • Peervoice
  • Peregrine Pharmaceuticals Inc.
  • Pfizer Oncology
  • Pharmadab d.o.o.
  • PharmaMar
  • Pierre Fabre Medicament
  • Pivotal SL
  • prIME Oncology
  • Quintiles
  • Sandoz International GmbH
  • Sanofi Genzyme
  • Servier
  • Shire
  • Sirtex Medical Europe GmbH
  • Sotio a.s.
  • Sysmex Inostics GmbH
  • Tesaro
  • Teva Pharmaceuticals Europe BV
  • Varian Medical Systems International AG
  • Wisepress Ltd.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.